PDCD1 and nasopharyngeal carcinoma: In spite of the fact that PD-1/PD-L1 immunocheckpoint inhibitor therapy has enhanced the prognosis of patients with NPC, it is currently only helpful for a few patients and has some disadvantages that cannot be ignored.